We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

INBIOS INTERNATIONAL

InBios International, Inc. is a biotechnology company specializing in the design, development and manufacture of immu... read more Featured Products: More products

Download Mobile App




Urine Test Developed for Congenital Chagas Disease

By LabMedica International staff writers
Posted on 09 Nov 2014
A Chagas urine nanoparticle test (Chunap) has been developed to concentrate, preserve and detect Trypanosoma cruzi antigens in urine for early, noninvasive diagnosis of congenital Chagas disease.

The conventional diagnosis of congenital Chagas disease is based on microscopy at birth and serology at nine months; however microscopy misses many infections and many at-risk infants fail to complete serology at six to nine months.

A team of international scientists led by those at Johns Hopkins University (Baltimore, MD, USA) collected 74 urine samples from Bolivian infants without congenital infection and 23 specimens from infants with congenital infection whose urine collection occurred prior to initiation of antitrypanosomal treatment. More...
Urine samples from 12 seronegative infants from Lima (Peru) were collected as non-endemic negative controls. Blood samples from infants obtained at birth and one month were evaluated by the micromethod, using a microscope, and polymerase chain reaction (PCR).

The screening specimens were tested by two rapid diagnostic tests (RDTs): an indirect hemagglutination test (IHA), and Chagas Detect, an immunochromatographic strip assay (InBios International; Seattle, WA, USA). The team evaluated the ability of the Poly N-isopropylacrylamide nanoparticles functionalized with trypan blue and synthesized by precipitation polymerization and characterized with photon correlation spectroscopy, to capture, concentrate and preserve T. cruzi antigens.

Urine samples from congenitally infected and uninfected infants were then concentrated using these nanoparticles. The antigens were eluted and detected by Western Blot using a monoclonal antibody against T. cruzi lipophosphoglycan. Visualization of antigenic bands was done using an enhanced chemiluminescence system (Supersignal West Dura, Thermo Fisher Scientific; Rockford, IL, USA). The Chunap test was carried out by a laboratory biologist who was also blinded to the Chagas status of the patient.

The nanoparticles concentrated T. cruzi antigens by 100 fold with the western blot detection limit decreased from 50 ng/mL to 0.5 ng/mL. The sensitivity of Chunap in a single specimen at one month of age was 91.3% (21/23) comparable to PCR in two specimens at birth and one month and significantly higher than microscopy in two specimens. Chunap specificity was 96.5%, 71/74 for endemic, 12/12 for non-endemic specimens. The cumulative sensitivity of micromethod and PCR was 34.8% (8/23) and 91.3% (21/23), respectively. Particle-sequestered T. cruzi antigens were protected from trypsin digestion.

The authors concluded that Chunap has the potential to enable early point-of-care diagnosis of congenital Chagas disease in peripheral health facilities. Further steps will be necessary to apply this nanotechnology in developing countries. The team is currently optimizing a novel separation method based on magnetic labeling of capturing nanoparticles to enable particle separation from urine without the need for a high speed centrifuge. Although used in this study for Chagas disease, this method could be adapted for detection of other parasitic infections in urine and other body fluids. The study was published on October 2, 2014 in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

Johns Hopkins University 
InBios International
Thermo Fisher Scientific 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.